newsfilter
← Latest News
GlobeNewswire·

Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to optimize competitive